Welcome to our dedicated page for Arcturus Therapeutics Holdings news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings stock.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), founded in 2013 and based in San Diego, California, is a pioneering RNA medicines company focused on developing novel therapeutics for rare diseases, particularly those with no adequate treatments. Specializing in RNA interference (RNAi) technologies, Arcturus is at the forefront of creating breakthrough treatments aimed at liver and respiratory diseases.
Arcturus operates primarily in the research and development sector, focusing on nucleic acid-based medical applications. Core technologies include its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA), enabling a versatile range of RNA therapeutics. Its mRNA drug substance and product manufacturing expertise further position Arcturus as a leader in RNA-based solutions.
Key projects in Arcturus' pipeline include:
- LUNAR-OTC for treating ornithine transcarbamylase deficiency
- LUNAR-CF aimed at cystic fibrosis
- LUNAR-FLU and LUNAR-COV19 for influenza and COVID-19 vaccines respectively
Recently, Arcturus announced a collaborative research endeavor with PassPort Technologies Inc. (PPTI) to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics. This partnership leverages ARCT’s LUNAR® platform and PPTI’s PassPort® transdermal technology, aiming to enhance the delivery and efficacy of RNA-based treatments.
Further cementing its competitive edge, Arcturus has developed Kostaive®, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine. Arcturus continues its global collaboration with CSL Seqirus for mRNA vaccines and maintains a joint venture in Japan, ARCALIS, to manufacture mRNA vaccines and therapeutics. The company’s extensive patent portfolio, covering over 400 patents across the U.S., Europe, Japan, China, and other countries, underscores its innovative prowess.
Financially, Arcturus maintains a solid growth trajectory, driven by its robust research initiatives and strategic alliances. For more detailed information, visit their official website at www.ArcturusRx.com, and connect via Twitter and LinkedIn.
Arcturus Therapeutics (Nasdaq: ARCT), a global leader in mRNA medicines, announced its participation in several upcoming investor and scientific conferences. These include the TIDES USA on May 16, 2024, H.C. Wainwright BioConnect on May 20, 2024, Piper Sandler Lung Investor Conference on May 23, 2024, and Goldman Sachs Healthcare Conference on June 12, 2024. These events will feature presentations and fireside chats, providing the company with opportunities to showcase its advancements in infectious disease vaccines and treatments for liver and respiratory rare diseases.
Arcturus Therapeutics announces a positive first-quarter financial update and pipeline progress. The commercial manufacture of Kostaive is on track for the delivery of 4 million doses in Q3. The European Marketing Authorization decision is expected in Q3. Multiple Phase 3 trials demonstrate the breadth of the STARR vaccine platform. Important Phase 1 data for ARCT-2138 is anticipated in Q3. JP Morgan will monetize the company's investment in ARCALIS JV in Japan. Financially, revenues decreased due to the CSL agreement, while operating expenses increased. The net loss was $26.8 million, but the cash position remains strong, with a cash runway of at least three years.
FAQ
What is the current stock price of Arcturus Therapeutics Holdings (ARCT)?
What is the market cap of Arcturus Therapeutics Holdings (ARCT)?
What does Arcturus Therapeutics specialize in?
What are the core technologies of Arcturus Therapeutics?
What kind of diseases is Arcturus targeting with its therapies?
What recent collaborations has Arcturus entered into?
What is Kostaive®?
Who are Arcturus' major partners?
What is LUNAR-OTC?
How extensive is Arcturus' patent portfolio?
Where is Arcturus Therapeutics headquartered?
How can I get more information about Arcturus Therapeutics?
